Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device.

Cengiz E, Weinzimer SA, Sherr JL, Tichy E, Martin M, Carria L, Steffen A, Tamborlane WV.

Pediatr Diabetes. 2013 May;14(3):168-73. doi: 10.1111/pedi.12001. Epub 2012 Oct 28.

2.

Faster in and faster out: accelerating insulin absorption and action by insulin infusion site warming.

Cengiz E, Weinzimer SA, Sherr JL, Tichy EM, Carria L, Cappiello D, Steffen A, Tamborlane WV.

Diabetes Technol Ther. 2014 Jan;16(1):20-5. doi: 10.1089/dia.2013.0187. Epub 2013 Dec 24.

3.

Improved pharmacokinetic and pharmacodynamic profiles of insulin analogues using InsuPatch, a local heating device.

Landau Z, Klonoff D, Nayberg I, Feldman D, Levit SB, Lender D, Mosenzon O, Raz I, Wainstein J.

Diabetes Metab Res Rev. 2014 Nov;30(8):686-92. doi: 10.1002/dmrr.2536.

PMID:
24610683
4.

Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart.

Heise T, Hövelmann U, Brøndsted L, Adrian CL, Nosek L, Haahr H.

Diabetes Obes Metab. 2015 Jul;17(7):682-8. doi: 10.1111/dom.12468. Epub 2015 May 8.

5.

Improved Postprandial Glucose Control Using the InsuPad Device in Insulin-Treated Type 2 Diabetes: Injection Site Warming to Improve Glycemic Control.

Raz I, Bitton G, Feldman D, Alon T, Pfutzner A, Tamborlane WV.

J Diabetes Sci Technol. 2015 May;9(3):639-43. doi: 10.1177/1932296815578881. Epub 2015 Apr 16.

6.
7.

Use of recombinant human hyaluronidase to accelerate rapid insulin analogue absorption: experience with subcutaneous injection and continuous infusion.

Vaughn DE, Muchmore DB.

Endocr Pract. 2011 Nov-Dec;17(6):914-21. doi: 10.4158/EP11297.RA. Review.

PMID:
22138081
8.

The alteration of aspart insulin pharmacodynamics when mixed with detemir insulin.

Cengiz E, Swan KL, Tamborlane WV, Sherr JL, Martin M, Weinzimer SA.

Diabetes Care. 2012 Apr;35(4):690-2. doi: 10.2337/dc11-0732. Epub 2012 Feb 28.

9.

Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial.

Ruan Y, Elleri D, Allen JM, Tauschmann M, Wilinska ME, Dunger DB, Hovorka R.

Diabetologia. 2015 Apr;58(4):687-90. doi: 10.1007/s00125-014-3483-6. Epub 2014 Dec 24.

10.

Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects.

Haahr H, Sasaki T, Bardtrum L, Ikushima I.

J Diabetes Investig. 2016 Jul;7(4):574-80. doi: 10.1111/jdi.12461. Epub 2016 Feb 4.

11.

Effect of age of infusion site and type of rapid-acting analog on pharmacodynamic parameters of insulin boluses in youth with type 1 diabetes receiving insulin pump therapy.

Swan KL, Dziura JD, Steil GM, Voskanyan GR, Sikes KA, Steffen AT, Martin ML, Tamborlane WV, Weinzimer SA.

Diabetes Care. 2009 Feb;32(2):240-4. doi: 10.2337/dc08-0595. Epub 2008 Nov 18.

13.

Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes.

Cengiz E, Tamborlane WV, Martin-Fredericksen M, Dziura J, Weinzimer SA.

Diabetes Care. 2010 May;33(5):1009-12. doi: 10.2337/dc09-2118. Epub 2010 Feb 11.

14.
15.

A comparison of pharmacokinetics and pharmacodynamics of insulin aspart, biphasic insulin aspart 70, biphasic insulin aspart 50, and human insulin: a randomized, quadruple crossover study.

Ma Z, Parkner T, Frystyk J, Laursen T, Lauritzen T, Christiansen JS.

Diabetes Technol Ther. 2012 Jul;14(7):589-95. doi: 10.1089/dia.2011.0299. Epub 2012 Apr 20.

PMID:
22519735
16.
17.

Time-action profile and patient assessment of inhaled insulin via the Exubera device in comparison with subcutaneously injected insulin aspart via the FlexPen device.

Forst T, Hohberg C, Schöndorf T, Borchert M, Forst S, Roth W, Dehos B, Pfützner A.

Diabetes Technol Ther. 2009 Feb;11(2):87-92. doi: 10.1089/dia.2008.0039.

PMID:
19848574
18.

Enhanced absorption of insulin aspart as the result of a dispersed injection strategy tested in a randomized trial in type 1 diabetic patients.

Mader JK, Birngruber T, Korsatko S, Deller S, Köhler G, Boysen S, Augustin T, Mautner SI, Sinner F, Pieber TR; AP@home Consortium..

Diabetes Care. 2013 Apr;36(4):780-5. doi: 10.2337/dc12-1319. Epub 2012 Nov 27.

19.

Increasing local blood flow by warming the application site: beneficial effects on postprandial glycemic excursions.

Freckmann G, Pleus S, Haug C, Bitton G, Nagar R.

J Diabetes Sci Technol. 2012 Jul 1;6(4):780-5. Review.

20.

Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection.

Pettis RJ, Ginsberg B, Hirsch L, Sutter D, Keith S, McVey E, Harvey NG, Hompesch M, Nosek L, Kapitza C, Heinemann L.

Diabetes Technol Ther. 2011 Apr;13(4):435-42. doi: 10.1089/dia.2010.0184. Epub 2011 Feb 28.

PMID:
21355718

Supplemental Content

Support Center